Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Sensitivity and specificity of ischaemia modified albumin in detecting diabetic nephropathy in T2DM

The Egyptian Journal of Internal Medicine volume 30, pages 204–211 (2018)Cite this article

Abstract

Background

Ischemia-modified albumin (IMA) is a novel marker of tissue ischemia and oxidative stress.

Aim

We assessed the level of IMA concentration in type 2 diabetes mellitus (T2DM) patients with diabetic nephropathy and its correlation with glycemia level, duration of diabetes, dyslipidemia, serum creatinine, and urinary albumin/creatinine ratio.

Patients and methods

This study included 91 patients who were divided into three groups: group A (33) included T2DM patients without nephropathy; group B (29) included T2DM patients with nephropathy; and group C (29) included healthy as control. Blood samples were analyzed manually for plasma IMA by spectrophotometric cobalt (II)-albuminbinding assay.

Results

Serum levels of IMA were significantly higher in group B in comparison to group A with a P value less than 0.001 and group C with a P value less than 0.0001. IMA positively correlated with blood pressure, duration of diabetes, fasting blood glucose, postprandial blood glucose, glycated hemoglobin, cholesterol, low-density lipoprotein, triglycerides, serum creatinine, and albumin/creatinine ratio, all with a P value less than 0.0001 and also with BMI (P<0.003). IMA was a significant discriminator for diabetic nephropathy (P<0.001) with 100% specificity and 100% sensitivity.

Conclusion

IMA could serve as an indicator of glycemic control and a sensitive marker of diabetic nephropathy.

References

  1. Bourdon E, Loreau N, Blanche D. Glucose and free radicals impair the antioxidant properties of serum albumin. FASEB J 1999; 12:233–244.

    Article  Google Scholar 

  2. Bar-Or D, Curtis G, Rao N, Bampos N, Lau E. Characterization of the CO2+ and Ni2+ binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 2001; 268:42–47.

    CAS  PubMed  Google Scholar 

  3. Christenson RH, Duh SH, Sanhai WR, Wu AH, Holtman V, Painter P, et al. Charateristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 2001; 47:464–470.

    Article  CAS  Google Scholar 

  4. Abboud H, Labreuche J, Meseguer E, Lavallee PC, Simon O, Olivot JM, et al. Ischemia-modified albumin in acute stroke. Cerebrovasc Dis 2007; 23:216–220.

    Article  CAS  Google Scholar 

  5. Borderie D, Allanore Y, Meune C, Devaux JY, Ekindjian OG, Kahan A. High ischemia-modified albumin concentration reflects oxidative stress but not myocardial involvement in systemic sclerosis. Clin Chem 2004; 50:2190–2193.

    Article  CAS  Google Scholar 

  6. Montagnana M, Lippi G. Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem 2006; 39:913–917.

    Article  CAS  Google Scholar 

  7. Roy D, Quiles J, Sharma R, Sinha M, Avanzas P, Gaze D, et al. Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. Clin Chem 2004; 50:1656–1660.

    Article  CAS  Google Scholar 

  8. Laver SR, Padkin A. Does hyperglycaemia precede the clinical onset of myocardial ischaemia?. Resuscitation 2005; 66:237–239.

    Article  Google Scholar 

  9. Montagnana M, Lippi G, Fava C, Minuz P, Santonastaso CL, Arosio E, et al. Ischemia-modified albumin and NT-prohormone-brain natriuretic peptide in peripheral arterial disease. Clin Chem Lab Med 2006; 44:207–212.

    CAS  PubMed  Google Scholar 

  10. Showell PJ, Matters DJ, Long JM, Carr-Smith H, Bradwell AR. Evaluation of latex-enhanced nephelometric reagents for measuring free immunoglobulin light-chains on a modified MININEPHTM. Clin Chem 2002; 48:A22–A22.

    Google Scholar 

  11. Choudhury JR, Karmakar A, Guha B, Das B, Rout J. Ischaemia modified albumin and malondialdehyde level in subjects suffering from hypothyroidism. Int J Biochem Res Rev 2015; 7:160–165.

    Article  Google Scholar 

  12. Ceriello A. Acute hyperglyceamia: a ‘new’ risk factor during myocardial infarction. Eur Heart J 2005; 26:328–331.

    Article  CAS  Google Scholar 

  13. Kalousová M, Skrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002; 51:597–604.

    PubMed  Google Scholar 

  14. Škva☒ilová M, Bulava A, Stejskal D, Adamovská S, Bartek J. Increased level of advanced oxidation products (AOPP) as a marker of oxidative stress in patients with acute coronary syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005; 149:83–87.

    Article  Google Scholar 

  15. Maritime AC, Sanders RA, Watkins JB III. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003; 17:24–38.

    Article  Google Scholar 

  16. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 2008; 4:444–452.

    Article  CAS  Google Scholar 

  17. Incerti J, Zelmanovitt T, Camargo JL, Gross JL, de Azevedo MJ. Evaluation of tests for microalbuminuria screening in patients with diabetes. Nephrol Dial Transplant 2005; 20:2402–2407.

    Article  Google Scholar 

  18. Jafar TH, Chaturvedi N, Hatcher J, Levvey AS. Use of albumin creatinine ratio and urine albumin concentration as a screening test for albuminuria in an Indol-Asian population. Nephrol Dial Transpant 2007; 22:2194–2200.

    Article  CAS  Google Scholar 

  19. Idris M, Hakki P, Fatma HY, Sevil K. Obesity is an independent determinant of ischemia-modified albumin. Obes Facts 2012; 5:700–709.

    Article  Google Scholar 

  20. Kawakami A, Kubota K, Yamda N, Tagami U, Takehana K, Sonaka I, et al. Identification and characterization of oxidized human serum albumin. A slight structural change impairs its ligand-binding and antioxidant functions. FEBS J 2006; 273:3346–3357.

    CAS  PubMed  Google Scholar 

  21. Pollock JS, Carmines PK. Diabetic nephropathy: nitric oxide and renal medullary hypoxia. Am J Physiol Renal Physiol 2008; 294:F28–F29.

    Article  CAS  Google Scholar 

  22. Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus. Preliminary report Dis Markers 2008; 24:311–317.

    Article  CAS  Google Scholar 

  23. Ukinc K, Eminagaoglu S, Ersoz HO, Erem C, Karahan C, Bayram HA, et al. A novel indicator of widespread endothelial damage and ischemia in diabetic patients. Ischemia-modified albumin. Endocrine 2009; 36: 425–432.

    CAS  PubMed  Google Scholar 

  24. Dash P, Manaswini M, Ray S. Ischaemia-modified albumin: an indicator of widespread endothelial damage in diabetes mellitus. J Physiobiochem Metab 2014; 3:1.

    Google Scholar 

  25. Dayanand CD, Vegi PK, Lakshmalah V, Kutty AVM. Association of ischemia modified albumin in terms of hypoxic risk with carbonylated protein, glycosylated haemoglobin and plasma insulin in type 2 diabetes. J Clin Diag Res 2013.

  26. Joha MS, Al Krita J, Ibraheem A. Influence of obesity on ischemia modified albumin and fructosamine levels. IJCBS Res Pap 2016; 2.

  27. Arslan B, Çuhadar S, Yiğitbaşı T, Uzun R, Örük G, Baskın Y, et al. Relationship between ischemia modified albumin and metabolic syndrome. Siriraj Med J 2015; 67.

  28. Yigitbasi T, Baskin Y, Akgol E, Calibasi Kocal G, Ellidokuz H. Association of ischemia-modified albumin with oxidative stress status and insulin resistance in obese patients. Rev Româ Med Lab 2017; 25.

  29. Chawla R, Loomba R, Guru D, Loomba V. Ischemia modified albumin – a marker ofglycaemic control and vascular complications in type 2 diabetes mellitus. J Clin Diagn Res 2016; 10:13–16.

    Google Scholar 

  30. Sowjanya UVPU, Sridevi C, Rajkumari DMM, Kasibabu A, et al. Study of ischemia modified albumin in type 2 diabetes as a marker of severity. J Dent Med Sci 2015; 14:14–17.

    Google Scholar 

  31. Patil P, Rao AV, Shetty S. Association of ischemia modified albumin with glycemic status in type II diabetes mellitus. Int J Recent Sci Res 2017; 8:15374–15378.

    Google Scholar 

  32. Ahmad A, Manjrekar P, Yadav C, Agarwal A, Srikantiah RM, Hegde A. Evaluation of ischemia-modified albumin, malondialdehyde, and advanced oxidative protein products as markers of vascular injury in diabetic nephropathy. Biomark Insights 2016; 11:63–68.

    Article  CAS  Google Scholar 

  33. Krzysek-Korpacka M, Neubauer K, Berdowska I, Boehm D, Zielinski B, Petryszyn P. Enhanced formation of advanced oxidation products in IBD. Inflamm Bowel Dis 2008; 14:749–802.

    Google Scholar 

  34. Refaat S, Abd El-Ghaffar N, Khalil A. The relationship between ischemia modified albumin and lipids in type 2 Egyptian diabetic patients. Adv Biol Res 2014; 8:18–22.

    Google Scholar 

  35. Kaefer M, Piva SJ, De Carvalho JAM, Da Silva DB, Becker AM, Coelho AC, et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem 2010; 43:450–454.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Cairo University, Cairo, 11562, Egypt

    Nehal Hamdy El Said, Heba Morad Youssef Bahgat, Hussein Saeed El-Fishawy & Maha Assem Hussein MD

  2. Clinical and Chemical Pathology Department, National Research Center, Cairo, Egypt

    Nagwa Abd El Ghaffar Mohamed

  3. Internal Medicine Department, Ezbet El Borg Hospital, Cairo, Egypt

    Omar Farouk Mahmoud Saleh

Authors
  1. Nehal Hamdy El Said
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heba Morad Youssef Bahgat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hussein Saeed El-Fishawy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maha Assem Hussein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nagwa Abd El Ghaffar Mohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Omar Farouk Mahmoud Saleh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maha Assem Hussein MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Said, N.H.E., Bahgat, H.M.Y., El-Fishawy, H.S. et al. Sensitivity and specificity of ischaemia modified albumin in detecting diabetic nephropathy in T2DM. Egypt J Intern Med 30, 204–211 (2018). https://doi.org/10.4103/ejim.ejim_30_18

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_30_18

Keywords